New InhA Inhibitors Based on Expanded Triclosan and Di-Triclosan Analogues to Develop a New Treatment for Tuberculosis
(2021)
Journal Article
Chetty, S., Armstrong, T., Sharma Kharkwal, S., Drewe, W. C., De Matteis, C. I., Evangelopoulos, D., …Thomas, N. R. (2021). New InhA Inhibitors Based on Expanded Triclosan and Di-Triclosan Analogues to Develop a New Treatment for Tuberculosis. Pharmaceuticals, 14(4), Article 361. https://doi.org/10.3390/ph14040361
The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) has reinforced the need for the development of new anti-TB drugs. The first line drug isoniazid inhibits InhA. This is a prodrug requiring activation by... Read More about New InhA Inhibitors Based on Expanded Triclosan and Di-Triclosan Analogues to Develop a New Treatment for Tuberculosis.